LianBio Payments to Acquire Marketable Securities
LianBio (LIANY) reported Payments to Acquire Marketable Securities of $128.12 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2023-11-13
- LianBio payments to acquire marketable securities for the quarter ending 2023-09-30 was $40.31M, a 69.97% decline year-over-year.
- LianBio payments to acquire marketable securities for the quarter ending 2023-06-30 was $41.98M, a 28.08% increase year-over-year.
- LianBio payments to acquire marketable securities for the quarter ending 2023-03-31 was $45.83M, a 50.91% decline year-over-year.
- LianBio payments to acquire marketable securities for the quarter ending 2022-12-31 was $42.77M, a 72.41% decline year-over-year.
- LianBio payments to acquire marketable securities for fiscal 2022 was $303.14M, a 95.58% increase from fiscal 2021.
- LianBio payments to acquire marketable securities for fiscal 2021 was $154.99M.
- LianBio payments to acquire marketable securities for fiscal 2020 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2023-09-30 | $40.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $82.29M derived: sum of 2 quarters · filed 2023-11-13 | $128.12M 10-Q · filed 2023-11-13 | $170.89M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $41.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $87.81M 10-Q · filed 2023-08-14 | $130.57M derived: sum of 3 quarters · filed 2023-08-14 | $264.80M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | $45.83M 10-Q · filed 2023-05-11 | $88.60M derived: sum of 2 quarters · filed 2023-05-11 | $222.83M derived: sum of 3 quarters · filed 2023-11-13 | $255.60M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $42.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $177.00M derived: sum of 2 quarters · filed 2023-11-13 | $209.77M derived: sum of 3 quarters · filed 2023-11-13 | $303.14M 10-K · filed 2023-03-28 |
| 2022-09-30 | $134.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $167.00M derived: sum of 2 quarters · filed 2023-11-13 | $260.37M 10-Q · filed 2023-11-13 | $415.36M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $32.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $126.14M 10-Q · filed 2023-08-14 | $281.13M derived: sum of 3 quarters · filed 2023-08-14 | $281.13M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $93.36M 10-Q · filed 2023-05-11 | $248.35M derived: sum of 2 quarters · filed 2023-05-11 | $248.35M derived: sum of 3 quarters · filed 2023-05-11 | $248.35M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $154.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $154.99M derived: sum of 2 quarters · filed 2023-03-28 | $154.99M derived: sum of 3 quarters · filed 2023-03-28 | $154.99M 10-K · filed 2023-03-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-31 |